STOCK TITAN

Alx Oncology Holdings Inc - ALXO STOCK NEWS

Welcome to our dedicated page for Alx Oncology Holdings news (Ticker: ALXO), a resource for investors and traders seeking the latest updates and insights on Alx Oncology Holdings stock.

Overview

ALX Oncology Holdings Inc (NASDAQ: ALXO) is a clinical‐stage biotechnology company dedicated to advancing innovative immuno‐oncology therapies. With a deep expertise in protein engineering, ALX Oncology is focused on developing treatments that block the CD47 immune checkpoint—a mechanism by which cancer cells signal the immune system not to attack. This approach is particularly significant in the context of enhancing both the innate and adaptive immune responses against malignancies. Keywords such as immuno‐oncology, CD47 blockade, and checkpoint inhibitor are central to the company’s identity and strategic direction.

Core Technology and Therapeutic Approach

The company’s lead product candidate, evorpacept, is a fusion protein that integrates an engineered, high-affinity CD47 binding domain with an inactivated Fc region, designed to minimize hematologic toxicities common to other CD47 blocking agents. This strategic design not only optimizes safety but also allows for potentially higher dosing in combination regimens. By mitigating the "don't eat me" signal of CD47, the therapy aims to restore the immune system’s ability to recognize and eliminate cancer cells. This precision in molecular design underlines ALX Oncology’s commitment to developing next-generation immunotherapies.

Clinical Development and Research Focus

ALX Oncology has built a robust clinical-stage pipeline that explores various combination strategies, investigating evorpacept with established anti-cancer antibodies, ADCs, and checkpoint inhibitors. The company conducts multiple studies across hematologic and solid malignancies, using its therapeutic candidate as a combinatorial partner to address complex cancer pathologies. While avoiding specific numerical data and time-sensitive details, it is evident that the clinical program is designed with a strong emphasis on advanced safety profiles and meaningful anti-tumor activity.

Market Position and Competitive Differentiation

Within the competitive landscape of immunotherapies, ALX Oncology differentiates itself through its innovative approach to CD47 blockade. Unlike competitors using active Fc domains, evorpacept employs an inactivated Fc region to reduce overlapping toxicities, potentially allowing effective higher dosing when used in combination with other therapies. This nuanced approach not only enhances its safety profile but also positions the company as an important contributor to evolving cancer treatment paradigms. The company’s strategic focus on combination therapies reflects a broader industry trend, wherein multi-modality treatment regimens are increasingly recognized for their potential to overcome resistance mechanisms in cancer cells.

Scientific and Clinical Expertise

ALX Oncology’s efforts are supported by a team with extensive experience in oncology, immunology, and biopharmaceutical research. The company integrates cutting-edge scientific advancements with clinical insights to drive its development programs. The rigorous, data-driven approach in its clinical trials underscores a commitment to high standards of scientific inquiry and patient safety. Moreover, the use of rational design principles in developing evorpacept demonstrates the company’s methodical and evidence-based approach to overcoming conventional therapeutic limitations.

Strategic Focus

The company remains focused on enhancing therapeutic outcomes by leveraging its product pipeline to bridge innate and adaptive immunity. Through collaborations and combination studies, ALX Oncology aims to address complex oncologic challenges while ensuring that its therapies maintain a broad applicability across multiple cancer indications. Each study is designed to provide insights into treatment efficacy and safety, contributing to an evolving landscape of immuno-oncology research that emphasizes precision, tolerability, and synergistic potential with other anti-cancer modalities.

Conclusion

In summary, ALX Oncology Holdings Inc. embodies a forward-thinking approach in the realm of immuno-oncology by targeting the CD47 checkpoint with a uniquely engineered candidate. The company’s integration of advanced protein design, strong clinical trial data, and a focus on combinational therapies places it in a notable position within the competitive biotechnology sector. This comprehensive approach not only highlights its scientific and clinical rigor but also provides a clear understanding of its business model and market significance for investors and industry observers alike.

Rhea-AI Summary
ALX Oncology appoints Jason Lettmann as CEO and Dr. Jaume Pons transitions to Chief Scientific Officer. Lettmann brings extensive experience in the biotechnology industry and has been involved with ALX Oncology since its founding. Pons will focus on supporting evorpacept and pipeline extension programs. Lettmann's appointment comes as the company's lead platform asset, evorpacept, advances to later stages of clinical development. Phase 2 data for evorpacept's ASPEN-06 program in HER2-positive gastric cancer is expected in Q4'23.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.37%
Tags
management
-
Rhea-AI Summary
ALX Oncology Holdings Inc. to participate in two upcoming investor conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.07%
Tags
none
-
Rhea-AI Summary
ALX Oncology Holdings Inc. (ALXO) advances Phase 2/3 ASPEN-06 gastric cancer trial with data update expected in Q423. Terminating ASPEN-02 in MDS and ASPEN-05 in AML. Continuing focus on combinations with anti-cancer antibodies, antibody-drug conjugates, and PD-1/PD-L1 immune checkpoint inhibitors. Financial results for Q2 2023 reported.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
Rhea-AI Summary

ALX Oncology Holdings Inc. (Nasdaq: ALXO) announced that its next-generation CD47 blocker, evorpacept, has received orphan drug designation (ODD) from the European Commission for treating gastric cancer patients. This designation covers both gastric cancer and gastroesophageal junction adenocarcinoma. The U.S. FDA had previously granted ODD to evorpacept for the same indication in January 2022.

Dr. Sophia Randolph, Chief Medical Officer at ALX Oncology, highlighted the significance of this regulatory achievement and the growing recognition of evorpacept's potential in improving clinical outcomes for gastric cancer patients. The company plans to present data from ASPEN-06, a randomized Phase 2 trial of evorpacept in combination with other drugs for HER2-positive gastric cancer, in the second half of 2023.

The EC grants orphan drug designation to medicines treating rare conditions affecting no more than five in 10,000 people in the EU. This status provides financial and regulatory incentives, including ten years of market exclusivity if approved for marketing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.9%
Tags
-
Rhea-AI Summary
ALX Oncology Holdings Inc. reported financial results for Q1 2023, with cash, cash equivalents, and investments of $256.2 million. R&D expenses were $24.8 million, and G&A expenses were $7.4 million. The GAAP net loss was $30.2 million. Recent clinical developments include the initiation of multiple clinical trials for evorpacept in combination with other drugs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.15%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.36%
Tags
Rhea-AI Summary

ALX Oncology (Nasdaq: ALXO) recently announced a collaboration with Sanofi to evaluate the combination of evorpacept, a CD47 blocker, and SARCLISA (isatuximab-irfc) in treating patients with relapsed or refractory multiple myeloma (RRMM). This collaboration involves a Phase 1/2 study focused on assessing the safety, efficacy, and pharmacokinetics of the combination therapy. The study aims to identify the optimal dosing and evaluate its efficacy in a broader patient population. ALX will supply evorpacept while Sanofi will provide SARCLISA. This partnership represents a significant step in developing combination therapies for multiple myeloma, which currently lacks a definitive cure.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.37%
Tags
-
Rhea-AI Summary

ALX Oncology Holdings Inc. (Nasdaq: ALXO) announced dosing of the first patient in the I-SPY-P1-TRIAL, sponsored by Quantum Leap Healthcare Collaborative, for treating unresectable or metastatic HER2-positive and HER2-low breast cancer. This Phase 1 study evaluates evorpacept, a CD47 blocker, combined with ENHERTU® (fam-trastuzumab deruxtecan-nxki) to assess safety, tolerability, and efficacy. Dr. Laura Esserman highlighted that this treatment may be transformative for patients resistant to other therapies. The I-SPY TRIAL aims to rapidly screen and test novel therapies tailored to specific patient subgroups.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.45%
Tags
none
-
Rhea-AI Summary

ALX Oncology Holdings reported its financial results for Q4 and the full year 2022, highlighting significant progress in clinical trials for its lead product, evorpacept. The company experienced a GAAP net loss of $30.7 million for Q4 2022, up from $28.4 million in Q4 2021, and a full-year GAAP net loss of $123.5 million, compared to $83.5 million in 2021. R&D expenses rose to $25.2 million for Q4 and $98.4 million for the year, reflecting ongoing development efforts. ALX has sufficient cash reserves of $282.9 million, expected to fund operations through mid-2025. The company anticipates key trial data presentations and IND filings in 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.18%
Tags
Rhea-AI Summary

ALX Oncology Holdings (Nasdaq: ALXO) announced the dosing of the first patient in the ASPEN-07 study, evaluating evorpacept, a novel CD47 blocker, in combination with PADCEV (enfortumab vedotin-ejfv) for urothelial cancer (UC). This Phase 1, open-label study aims to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with unresectable advanced UC (NCT05524545). Given the poor outcomes and limited treatments available post-chemotherapy for this patient group, the study seeks to investigate a new therapy that may enhance efficacy without increasing toxicity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.74%
Tags

FAQ

What is the current stock price of Alx Oncology Holdings (ALXO)?

The current stock price of Alx Oncology Holdings (ALXO) is $0.5159 as of April 4, 2025.

What is the market cap of Alx Oncology Holdings (ALXO)?

The market cap of Alx Oncology Holdings (ALXO) is approximately 27.2M.

What is the core focus of ALX Oncology Holdings Inc.?

ALX Oncology is focused on developing innovative immuno-oncology therapies, particularly by targeting the CD47 immune checkpoint to help the immune system combat cancer.

How does evorpacept, the company’s lead candidate, work?

Evorpacept is a fusion protein that combines a high-affinity CD47 binding domain with an inactivated Fc region, designed to block the CD47 'don’t eat me' signal and enhance immune recognition of cancer cells.

What makes ALX Oncology’s approach to CD47 blockade unique?

The company’s approach uses an inactivated Fc domain to minimize hematologic toxicities, allowing for higher therapeutic dosing when used in combination with other anti-cancer agents.

In which areas is ALX Oncology conducting clinical studies?

ALX Oncology is engaged in clinical trials across various hematologic and solid malignancies, often exploring combination regimens with standard anticancer antibodies, ADCs, and checkpoint inhibitors.

How does ALX Oncology differentiate itself in the competitive immuno-oncology market?

ALX Oncology differentiates itself through its precise protein engineering, the unique safety profile of evorpacept, and its strategic focus on combination therapies that bridge innate and adaptive immunity.

What is the significance of targeting the CD47 checkpoint in cancer therapy?

Targeting the CD47 checkpoint is significant because it interrupts a key mechanism that cancer cells use to avoid immune detection, thereby potentially enhancing the efficacy of cancer treatments.

What role does combination therapy play in ALX Oncology’s research strategy?

Combination therapy is integral to their strategy as it aims to leverage the benefits of evorpacept alongside other anti-cancer agents, increasing therapeutic efficacy and addressing resistance mechanisms.

Who are the typical stakeholders interested in ALX Oncology’s developments?

Investors, clinicians, and researchers with an interest in cutting-edge immuno-oncology and targeted cancer therapies are the primary stakeholders following ALX Oncology’s clinical advancements.
Alx Oncology Holdings Inc

Nasdaq:ALXO

ALXO Rankings

ALXO Stock Data

27.22M
42.55M
2.03%
89.37%
11.03%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO